• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

SteadyMed tops Q2 sales estimates

August 11, 2017 By Sarah Faulkner

SteadyMed TherapeuticsShares in SteadyMed (NSDQ:STDY) fell today after the pharmaceutical company beat sales expectations on Wall Street with its second quarter results, but missed EPS estimates.

The San Ramon, Calif.-based company posted a net loss of -$8.1 million on sales of $319,000 for the 3 months ended June 30, for bottom-line loss of -14% on sales growth of 239.4% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were -33¢, behind consensus on The Street, where analysts were looking for sales of $130,000 million.

“SteadyMed has had a very successful year to date, culminating in the June 30, 2017 submission of an NDA for our lead drug candidate, Trevyent. PAH is a serious, life threatening disease, and currently, the administration of high dose prostacyclins to help these patients has some serious challenges. Trevyent has been developed with the aim of addressing these challenges,” president & CEO Jonathan Rigby said in prepared remarks. “We completed the second quarter with a strong cash position of $43.5 million. We believe this provides the necessary foundation to execute on our next major milestones for the company through the launch of Trevyent in the U.S., which is anticipated in mid-2018, subject to FDA approval.”

STDY shares were trading at $6.22 apiece today in afternoon activity, down -1.3%.

In April, the company inked a $30 million private placement with Adage Capital Management, OrbiMed, Deerfield Management and Kingon Capital Management.

SteadyMed said it plans to use its newly-acquired funds to prepare for the commercial launch of its pulmonary arterial hypertension treatment, Trevyent. The therapy is a combination of treprostinil and the PatchPump prefilled, disposable infusion system.

See the best minds in medtech live at DeviceTalks Boston on Oct. 2.

Filed Under: Cardiovascular, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: SteadyMed Therapeutics

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS